FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988825289> ?p ?o ?g. }

• W2988825289 endingPage "124" @default.
• W2988825289 startingPage "124" @default.
• W2988825289 abstract "Introduction Limited stage follicular lymphoma (FL) is usually managed with involved field radiotherapy (IFRT), although different approaches are currently carried out, ranging from watch and wait to combined treatment. RT on involved lymph nodes allows eradication of the disease only in 40-50% of patients. Anti-CD20 monoclonal antibodies (MoAb), widely used in advanced stage FL, are likely to be effective in reducing the relapse risk, although no scientific evidence of their role has been provided. The aim of this multicenter phase II prospective study was to evaluate the role of MRD in identifying patients unlikely to be cured by RT, for whom an immunotherapy-based consolidation could improve outcome. Methods 110 patients with stage I/II FL were enrolled. IFRT was administered to all patients at a dose of 24 Gy. Peripheral blood (PB) and bone marrow (BM) samples were centralized to the Italian FIL (Federazione Italiani Linfomi) MRD Network of EuroMRD-certified laboratories: the presence of a BCL2/IGH rearrangement was investigated at baseline in all patients by nested PCR (NEST) and RQ-PCR (RQ), the latter according to the EuroMRD guidelines. In patients BCL2/IGH+ at baseline by both NEST and RQ in BM and/or PB, MRD was analyzed in both tissues after IFRT and every 6 months over a three-year follow-up period. Patients with positive MRD by both NEST and RQ in BM and/or PB after IFRT or who became positive during the follow-up were treated with 8 weekly doses of the anti-CD20 MoAb ofatumumab. The primary objective of the study was to define the efficacy of immunotherapy in obtaining the disappearance of BCL2/IGH rearranged cells. Results Preliminary data are available for 107 patients, 57 males, 50 females. Median age was 55 years (29-83). 17% had G1 FL, 32% G2, 40% G3A, 11% NOS. The FLIPI score was 0 in 59% of patients, 1 in 35%, 2 in 6%. 69% of patients had inguinal site involvement. Despite a negative BM biopsy, at baseline 30% of patients (n=32) had a BCL2/IGH rearrangement (30 MBR, 1 MBR and mcr, 1 mcr) in the BM and/or PB; the concordance between compartments was 90%, with 10% of negative PB showing a positive BM. No significant differences were observed in relapse probability between patients with or without a molecular marker. All patients were submitted to IFRT and all obtained a clinical response, which was complete in 79 of the 101 evaluated patients (78%) and partial in 22 (22%). MRD evaluation after treatment revealed the persistence of BCL2/IGH rearranged cells in the PB and/or BM in 60% of patients. According to the design of the protocol, MRD-positive patients, either after IFRT (n=18) or in case of conversion to a positive signal during the follow-up (n=7), received 8 weekly administration of ofatumumab. A conversion to MRD negativity, evaluated in 23 treated patients, was obtained in 20 (87% - CI 65.1-97.1). This result was significantly superior to the expected 50%. One death occurred after IFRT, due to ischemic stroke. Adverse events likely correlated to ofatumumab occurred in 7/25 treated patients, consisting of infusion reactions in 5, leading to a permanent interruption of immunotherapy in 3. After a median follow-up of 18 months, all patients who achieved a MRD negativity with ofatumumab underwent a regular molecular follow-up and are still MRD-negative. Overall, clinical relapse or progression were observed in 17 patients: 13 (18%) among the 73 no marker patients; 2 relapses (16%) were observed among the 12 MRD-negative patients after IFRT and 2 relapses were observed among the 23 patients treated with the anti-CD20 MoAb (8.7%), 1 having achieved a MRD negativity and 1 not. No significant differences in event-free survival have so far been observed between the three groups. Conclusions The MRD data of this phase II trial for early stage FL indicate that RT alone is often insufficient to eradicate the disease, being capable of inducing a negative MRD only in 40% of evaluable cases, with a long-lasting effect only in half of them. The primary objective of this study - MRD negativity after immunotherapy - was achieved, obtaining the disappearance of BCL2/IGH rearranged cells in the majority of patients treated with ofatumumab. The strategy of an immunotherapy consolidation after IFRT in MRD-positive patients allowed to increase molecular responses. A longer follow-up and further studies on larger patient populations will allow to conclusively define the impact of this MRD-driven strategy also on clinical outcome. Disclosures Pulsoni: Roche: Consultancy, Speakers Bureau; Takeda: Consultancy; Pfizer: Consultancy; Sandoz: Consultancy; Gilead: Speakers Bureau; Merk: Consultancy; Bristol Meyer Squibb: Speakers Bureau. Ferrero:Servier: Speakers Bureau; EUSA Pharma: Membership on an entity's Board of Directors or advisory committees; Gilead: Speakers Bureau; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Luminari:ROCHE: Other: Role as Advisor ; CELGENE: Other: Role as Advisor & Travel Grant; TAKEDA: Other: Travel Grant; GILEAD: Other: Lecturer . Liberati:Amgen: Membership on an entity's Board of Directors or advisory committees, Other: Clinical trial support; Celgene: Honoraria, Other: Clinical trial support; Bristol-Myers Squibb: Honoraria; Takeda: Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy; Janssen: Honoraria; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Clinical trial support; Roche: Other: Clinical trial support; Novartis: Other: Clinical trial support. Ferreri:Roche: Research Funding; Celgene: Consultancy, Research Funding; Novartis: Consultancy; Kite: Consultancy. Nassi:Takeda: Consultancy; Janssen: Consultancy; Merck: Consultancy. Corradini:Roche: Honoraria; Novartis: Honoraria; kite: Honoraria; KiowaKirin: Honoraria; Janssen: Honoraria; Gilead: Honoraria; Daiichi Sankyo: Honoraria; Celgene: Honoraria; Amgen: Honoraria; Abbvie: Honoraria; Servier: Honoraria; Sanofi: Honoraria; Takeda: Honoraria. Mannina:Janssen: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees. Arcaini:Celgene: Speakers Bureau; Gilead Sciences: Research Funding; Bayer, Celgene, Gilead Sciences, Roche, Sandoz, Janssen-Cilag, VERASTEM: Consultancy; Celgene, Roche, Janssen-Cilag, Gilead: Other: Travel expenses. Galimberti:Roche: Speakers Bureau; Celgene: Speakers Bureau; Novartis: Speakers Bureau. Ladetto:AbbVie: Honoraria; Roche: Honoraria; ADC Therapeutics: Honoraria; Acerta: Honoraria, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau; J&J: Honoraria; Celgene: Honoraria. Foà:Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Consultancy, Speakers Bureau; Roche: Consultancy, Speakers Bureau; Roche: Consultancy, Speakers Bureau; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celltrion: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Shire: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Consultancy, Speakers Bureau; Celltrion: Membership on an entity's Board of Directors or advisory committees; Amgen Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Shire: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. OffLabel Disclosure: The anti-CD20 MoAb Ofatumomab is employed to eradicate Minimal Residual Disease in early stage Follicular Lymphoma(FL). The drug is registered for Chronic Lymphocytic Leukemia, not for FL." @default.
• W2988825289 created "2019-11-22" @default.
• W2988825289 creator A5001285087 @default.
• W2988825289 creator A5009431453 @default.
• W2988825289 creator A5011319426 @default.
• W2988825289 creator A5012645361 @default.
• W2988825289 creator A5015128036 @default.
• W2988825289 creator A5016259297 @default.
• W2988825289 creator A5016803459 @default.
• W2988825289 creator A5016979013 @default.
• W2988825289 creator A5017472528 @default.
• W2988825289 creator A5019034145 @default.
• W2988825289 creator A5020410544 @default.
• W2988825289 creator A5022006811 @default.
• W2988825289 creator A5022552300 @default.
• W2988825289 creator A5022734562 @default.
• W2988825289 creator A5029614391 @default.
• W2988825289 creator A5031900135 @default.
• W2988825289 creator A5033131356 @default.
• W2988825289 creator A5034415866 @default.
• W2988825289 creator A5035628818 @default.
• W2988825289 creator A5037764279 @default.
• W2988825289 creator A5041169669 @default.
• W2988825289 creator A5042513487 @default.
• W2988825289 creator A5047961182 @default.
• W2988825289 creator A5049017377 @default.
• W2988825289 creator A5051412800 @default.
• W2988825289 creator A5052585491 @default.
• W2988825289 creator A5053560614 @default.
• W2988825289 creator A5060509370 @default.
• W2988825289 creator A5061089197 @default.
• W2988825289 creator A5069193615 @default.
• W2988825289 creator A5071466957 @default.
• W2988825289 creator A5071732201 @default.
• W2988825289 creator A5073179633 @default.
• W2988825289 creator A5076353357 @default.
• W2988825289 creator A5078444724 @default.
• W2988825289 creator A5079030265 @default.
• W2988825289 creator A5079136601 @default.
• W2988825289 creator A5081222292 @default.
• W2988825289 creator A5081247845 @default.
• W2988825289 creator A5082964368 @default.
• W2988825289 creator A5083045645 @default.
• W2988825289 creator A5085410438 @default.
• W2988825289 creator A5086529586 @default.
• W2988825289 date "2019-11-13" @default.
• W2988825289 modified "2023-10-14" @default.
• W2988825289 title "EARLY STAGE Follicular Lymphoma: First Results of the FIL Miro Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy" @default.
• W2988825289 doi "https://doi.org/10.1182/blood-2019-123106" @default.
• W2988825289 hasPublicationYear "2019" @default.
• W2988825289 type Work @default.
• W2988825289 sameAs 2988825289 @default.
• W2988825289 citedByCount "4" @default.
• W2988825289 countsByYear W29888252892020 @default.
• W2988825289 countsByYear W29888252892021 @default.
• W2988825289 countsByYear W29888252892022 @default.
• W2988825289 crossrefType "journal-article" @default.
• W2988825289 hasAuthorship W2988825289A5001285087 @default.
• W2988825289 hasAuthorship W2988825289A5009431453 @default.
• W2988825289 hasAuthorship W2988825289A5011319426 @default.
• W2988825289 hasAuthorship W2988825289A5012645361 @default.
• W2988825289 hasAuthorship W2988825289A5015128036 @default.
• W2988825289 hasAuthorship W2988825289A5016259297 @default.
• W2988825289 hasAuthorship W2988825289A5016803459 @default.
• W2988825289 hasAuthorship W2988825289A5016979013 @default.
• W2988825289 hasAuthorship W2988825289A5017472528 @default.
• W2988825289 hasAuthorship W2988825289A5019034145 @default.
• W2988825289 hasAuthorship W2988825289A5020410544 @default.
• W2988825289 hasAuthorship W2988825289A5022006811 @default.
• W2988825289 hasAuthorship W2988825289A5022552300 @default.
• W2988825289 hasAuthorship W2988825289A5022734562 @default.
• W2988825289 hasAuthorship W2988825289A5029614391 @default.
• W2988825289 hasAuthorship W2988825289A5031900135 @default.
• W2988825289 hasAuthorship W2988825289A5033131356 @default.
• W2988825289 hasAuthorship W2988825289A5034415866 @default.
• W2988825289 hasAuthorship W2988825289A5035628818 @default.
• W2988825289 hasAuthorship W2988825289A5037764279 @default.
• W2988825289 hasAuthorship W2988825289A5041169669 @default.
• W2988825289 hasAuthorship W2988825289A5042513487 @default.
• W2988825289 hasAuthorship W2988825289A5047961182 @default.
• W2988825289 hasAuthorship W2988825289A5049017377 @default.
• W2988825289 hasAuthorship W2988825289A5051412800 @default.
• W2988825289 hasAuthorship W2988825289A5052585491 @default.
• W2988825289 hasAuthorship W2988825289A5053560614 @default.
• W2988825289 hasAuthorship W2988825289A5060509370 @default.
• W2988825289 hasAuthorship W2988825289A5061089197 @default.
• W2988825289 hasAuthorship W2988825289A5069193615 @default.
• W2988825289 hasAuthorship W2988825289A5071466957 @default.
• W2988825289 hasAuthorship W2988825289A5071732201 @default.
• W2988825289 hasAuthorship W2988825289A5073179633 @default.
• W2988825289 hasAuthorship W2988825289A5076353357 @default.
• W2988825289 hasAuthorship W2988825289A5078444724 @default.
• W2988825289 hasAuthorship W2988825289A5079030265 @default.
• W2988825289 hasAuthorship W2988825289A5079136601 @default.
• W2988825289 hasAuthorship W2988825289A5081222292 @default.
• W2988825289 hasAuthorship W2988825289A5081247845 @default.
• W2988825289 hasAuthorship W2988825289A5082964368 @default.
• W2988825289 hasAuthorship W2988825289A5083045645 @default.

• next